Literature DB >> 7598246

Sodium nitroprusside: twenty years and counting.

J A Friederich1, J F Butterworth.   

Abstract

SNP remains an effective, reliable, and commonly used drug for the rapid reduction of significant arterial hypertension regardless of the etiology, for afterload reduction in the face of low CO when blood volume is normal or increased, and for intraoperative induced hypotension. After establishing indwelling arterial monitoring, an initial infusion rate of 0.3-0.5 micrograms.kg-1.min-1 is begun with titration as needed up to 2.0 micrograms.kg-1.min-1. Higher rates for brief periods of time (10 min) are acceptable. The use of alternative drugs to reduce the dose or shorten the duration of infusion should be considered when the 2.0 micrograms.kg-1.min-1 range is exceeded (Table 1). SNP should not be used by individuals unfamiliar with its potency and metabolic pathways, as the many reports of adverse reactions testify. Careful attention to infusion rates, particularly in patients at risk for depleted thiosulfate stores, is mandatory, and the use of other drugs in conjunction with or instead of SNP should always be considered. As with many therapeutic interventions, SNP requires careful administration to appropriately selected patients by a clinician who knows its inherent hazards. Despite its toxicity, SNP is popular because it is often the most (in some cases, the only) effective drug in some difficult clinical circumstances.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7598246     DOI: 10.1097/00000539-199507000-00031

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  48 in total

1.  Local response of L-type Ca(2+) current to nitric oxide in frog ventricular myocytes.

Authors:  M Dittrich; J Jurevicius; M Georget; F Rochais; B Fleischmann; J Hescheler; R Fischmeister
Journal:  J Physiol       Date:  2001-07-01       Impact factor: 5.182

2.  Note of caution for the use of sodium nitroprusside in neonatal hypertension.

Authors:  Christian von Schnakenburg; Marcus Krüger
Journal:  Pediatr Nephrol       Date:  2004-08-25       Impact factor: 3.714

3.  Photoactive Ruthenium Nitrosyls: Effects of Light and Potential Application as NO Donors.

Authors:  Michael J Rose; Pradip K Mascharak
Journal:  Coord Chem Rev       Date:  2008-10-01       Impact factor: 22.315

4.  In vivo target sites of nitric oxide in photosynthetic electron transport as studied by chlorophyll fluorescence in pea leaves.

Authors:  Barnabás Wodala; Zsuzsanna Deák; Imre Vass; László Erdei; István Altorjay; Ferenc Horváth
Journal:  Plant Physiol       Date:  2008-02-01       Impact factor: 8.340

Review 5.  Application of metal coordination chemistry to explore and manipulate cell biology.

Authors:  Kathryn L Haas; Katherine J Franz
Journal:  Chem Rev       Date:  2009-10       Impact factor: 60.622

6.  Clinical evaluation of an automatic blood pressure controller during cardiac surgery.

Authors:  R H Meijers; D Schmartz; F R Cantraine; L Barvais; A A d'Hollander; J A Blom
Journal:  J Clin Monit       Date:  1997-07

Review 7.  Control of blood pressure in hypertensive neurological emergencies.

Authors:  Lisa Manning; Thompson G Robinson; Craig S Anderson
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

8.  Therapeutic Interchange of Clevidipine For Sodium Nitroprusside in Cardiac Surgery.

Authors:  Joseph E Cruz; Zachariah Thomas; David Lee; David M Moskowitz; Jeff Nemeth
Journal:  P T       Date:  2016-10

9.  Effects of nitric oxide and its congeners on sickle red blood cell deformability.

Authors:  Andrea M Belanger; Christian Keggi; Tamir Kanias; Mark T Gladwin; Daniel B Kim-Shapiro
Journal:  Transfusion       Date:  2015-04-23       Impact factor: 3.157

10.  Parenteral clevidipine for the acute control of blood pressure in the critically ill patient: a review.

Authors:  W Frank Peacock; Jorge E Angeles; Karina M Soto; Philip D Lumb; Joseph Varon
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.